Detalhe da pesquisa
1.
A2A Adenosine Receptor Gene Deletion or Synthetic A2A Antagonist Liberate Tumor-Reactive CD8+ T Cells from Tumor-Induced Immunosuppression.
J Immunol;
201(2): 782-791, 2018 07 15.
Artigo
em Inglês
| MEDLINE
| ID: mdl-29802128
2.
Hypoxia-adenosinergic immunosuppression: tumor protection by T regulatory cells and cancerous tissue hypoxia.
Clin Cancer Res;
14(19): 5947-52, 2008 Oct 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-18829471
3.
Everolimus (RAD) inhibits in vivo growth of murine squamous cell carcinoma (SCC VII).
Laryngoscope;
116(5): 814-20, 2006 May.
Artigo
em Inglês
| MEDLINE
| ID: mdl-16652094
4.
Active immunotherapy for advanced intracranial murine tumors by using dendritic cell-tumor cell fusion vaccines.
J Neurosurg;
103(1): 156-64, 2005 Jul.
Artigo
em Inglês
| MEDLINE
| ID: mdl-16121986
5.
Tumor-dendritic cell fusion as a basis for cancer immunotherapy.
Otolaryngol Head Neck Surg;
132(5): 755-64, 2005 May.
Artigo
em Inglês
| MEDLINE
| ID: mdl-15886631
6.
Immunological mechanisms of the antitumor effects of supplemental oxygenation.
Sci Transl Med;
7(277): 277ra30, 2015 Mar 04.
Artigo
em Inglês
| MEDLINE
| ID: mdl-25739764
7.
Systemic oxygenation weakens the hypoxia and hypoxia inducible factor 1α-dependent and extracellular adenosine-mediated tumor protection.
J Mol Med (Berl);
92(12): 1283-92, 2014 Dec.
Artigo
em Inglês
| MEDLINE
| ID: mdl-25120128
8.
Significance of regional draining lymph nodes in the development of tumor immunity: implications for cancer immunotherapy.
Cancer Treat Res;
135: 223-37, 2007.
Artigo
em Inglês
| MEDLINE
| ID: mdl-17953420
9.
Mechanism of third signals provided by IL-12 and OX-40R ligation in eliciting therapeutic immunity following dendritic-tumor fusion vaccination.
Cell Immunol;
243(1): 30-40, 2006 Sep.
Artigo
em Inglês
| MEDLINE
| ID: mdl-17207783
10.
Electrofusion of syngeneic dendritic cells and tumor generates potent therapeutic vaccine.
Cell Immunol;
225(2): 65-74, 2003 Oct.
Artigo
em Inglês
| MEDLINE
| ID: mdl-14698141
11.
Therapeutic efficacy of adoptive immunotherapy is predicated on in vivo antigen-specific proliferation of donor T cells.
Clin Immunol;
108(1): 8-20, 2003 Jul.
Artigo
em Inglês
| MEDLINE
| ID: mdl-12865066
12.
Depletion of CD4+ CD25+ regulatory cells augments the generation of specific immune T cells in tumor-draining lymph nodes.
J Immunother;
25(3): 207-17, 2002.
Artigo
em Inglês
| MEDLINE
| ID: mdl-12000862
13.
Memory T cells originate from adoptively transferred effectors and reconstituting host cells after sequential lymphodepletion and adoptive immunotherapy.
J Immunol;
172(6): 3462-8, 2004 Mar 15.
Artigo
em Inglês
| MEDLINE
| ID: mdl-15004146
14.
Comparative analysis of antigen loading strategies of dendritic cells for tumor immunotherapy.
J Immunother;
27(4): 265-72, 2004.
Artigo
em Inglês
| MEDLINE
| ID: mdl-15235387
15.
Tumor-induced L-selectinhigh suppressor T cells mediate potent effector T cell blockade and cause failure of otherwise curative adoptive immunotherapy.
J Immunol;
169(9): 4811-21, 2002 Nov 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-12391191